via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced that it
will be represented during two upcoming scientific meetings,
including Vaccines Summit Boston 2023 in Boston, MA, May 22-24,
2023 and CYTO 2023 in Montréal, Québec, Canada, May 20-24, 2023.
Vaccines Summit Presentation: Monday, May 22, 2023,
3:00 pm -3:30 pm ET, Session Talks – II
On Monday, May 22, Don Diamond, Ph.D., Professor,
Department of Hematology & Hematopoietic Cell Transplantation,
City of Hope, will deliver a presentation titled, “Assessment of
GEO-CM04S1 for Prevention of COVID-19 in Immunocompromised Cell
Therapy Patients; An Open-Label Safety Study.”
Dr. Diamond’s presentation will include a
description of the development and clinical testing of GeoVax’s
vaccine candidate, GEO-CM04S1. CM04S1 is a next-generation COVID-19
vaccine based on the use of the MVA viral vector platform, which
presents multiple antigens to the immune system to induce both
antibody and T cell responses. The vaccine is designed to provide
durable protection against new and continually emerging variants of
COVID-19, limiting the need for frequent modification and
updating.
GeoVax is focusing on the clinical development of
this vaccine for use in patients with impaired ability to mount
adequate protective immune responses to currently available
COVID-19 vaccines, to include those with certain malignancies and
autoimmune disorders, cell and organ transplant patients,
individuals with end-stage kidney disease receiving hemodialysis,
and potentially elderly individuals who respond poorly to other
vaccines. These individuals may not be able to raise or
maintain protective antibody responses following receipt of
first-generation mRNA vaccines, contributing to reduced vaccine
efficacy.
Dr. Diamond’s presentation will include new and
unpublished data from the open-label portion of the Phase 2 trial
in patients undergoing hematological cancer treatment.
CYTO Poster Presentation: Tuesday, May
23, 2023, 5:30 pm – 6:00 pm ET, Exhibit Hall 210
On Tuesday, May 23, Sandra Ortega-Francisco,
Ph.D., Department of Hematology and Hematopoietic Cell
Transplantation and Hematologic Malignancies Research Institute,
City of Hope, will participate in a poster presentation
titled, “Induction of multi-antigen specific T cell responses
by a synthetic MVA-SARS-CoV-2 vaccine in patients with
hematological malignancies.”
Similar to the Vaccines Summit presentation by Dr.
Diamond, Dr. Ortega-Francisco’s poster presentation will also
address preliminary data from the ongoing Phase 2 study of CM04S1
in patients with hematologic malignancies who are at a heightened
risk of severe COVID-19.
About GEO-CM04S1
CM04S1 is a next-generation COVID-19 vaccine based
on GeoVax’s MVA viral vector platform, which supports the
presentation of multiple vaccine antigens to the immune system in a
single dose. CM04S1 presents both the spike and nucleocapsid
antigens of SARS-CoV-2 and is specifically designed to induce both
antibody and T cell responses to non-variable parts of the virus.
The more broadly specific and functional engagement of the immune
system is designed to provide protection against the new and
continually emerging variants of COVID-19. Based on data from
animal models and a completed Phase 1 clinical study,
vaccine-induced immune responses were shown to recognize both early
and later variants of SARS-CoV-2, including the Omicron variant.
Vaccines of this format should not require repeated modification
and updating.
CM04S1 continues to advance in two Phase 2
clinical studies, one as a primary vaccine for immunocompromised
cancer patients, in direct comparison to either the Pfizer or
Moderna mRNA vaccine (ClinicalTrials.gov
Identifier: NCT04977024), and the second as a booster for
healthy patients who have previously received either the Pfizer or
Moderna vaccine as their initial inoculation (ClinicalTrials.gov
Identifier: NCT04639466).
About GeoVax
GeoVax Labs, Inc. is a clinical-stage
biotechnology company developing novel therapies and vaccines for
solid tumor cancers and many of the world’s most threatening
infectious diseases. The company’s lead program in oncology is a
novel oncolytic solid tumor gene-directed therapy, Gedeptin®,
presently in a multicenter Phase 1/2 clinical trial for advanced
head and neck cancers. GeoVax’s lead infectious disease candidate
is GEO-CM04S1, a next-generation COVID-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in two
Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a
COVID-19 vaccine for immunocompromised patients such as those
suffering from hematologic cancers and other patient populations
for whom the current authorized COVID-19 vaccines are insufficient.
In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating
the vaccine as a more robust, durable COVID-19 booster among
healthy patients who previously received the mRNA vaccines. GeoVax
has a leadership team who have driven significant value creation
across multiple life science companies over the past several
decades. For more information, visit our website:
www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements
regarding GeoVax’s business plans. The words “believe,” “look
forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “could,” “target,” “potential,” “is likely,”
“will,” “expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is
contained in our periodic reports on Form 10-Q and Form 10-K that
we have filed and will file with the SEC. Any forward-looking
statement made by us herein speaks only as of the date on which it
is made. Factors or events that could cause our actual results to
differ may emerge from time to time, and it is not possible for us
to predict all of them. We undertake no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future developments or otherwise, except as may be
required by law.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GeoVax Labs (NASDAQ:GOVXW)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024